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Synthesis of Bis-Heterocyclic 1H-Imidazole 3-Oxides from
3-Oxido-1H-imidazole-4-carbohydrazides
Pieczonka, A M; Mloston, G; Heimgartner, H
Abstract: The reaction of 1H-imidazole-4-carbohydrazides 1, which are conveniently accessible by treat-
ment of the corresponding esters with NH2NH2·H2O, with isothiocyanates in refluxing EtOH led to
thiosemicarbazides (= hydrazinecarbothioamides) 4 in high yields (Scheme 2). Whereas 4 in boiling
aqueous NaOH yielded 2,4-dihydro-3H-1,2,4-triazole-3-thiones 5, the reaction in concentrated H2SO4 at
room temperature gave 1,3,4-thiadiazol-2-amines 6. Similarly, the reaction of 1 with butyl isocyanate
led to semicarbazides 7, which, under basic conditions, undergo cyclization to give 2,4-dihydro-3H-1,2,4-
triazol-3-ones 8 (Scheme 3). Treatment of 1 with Ac2O yielded the diacylhydrazine derivatives 9 ex-
clusively, and the alternative isomerization of 1 to imidazol-2-ones was not observed (Scheme 4). It is
important to note that, in all these transformations, the imidazole N-oxide residue is retained. Further-
more, it was shown that imidazole N-oxides bearing a 1,2,4-triazole-3-thione or 1,3,4-thiadiazol-2-amine
moiety undergo the S-transfer reaction to give bis-heterocyclic 1H-imidazole-2-thiones 11 by treatment
with 2,2,4,4-tetramethylcyclobutane-1,3-dithione (Scheme 5).
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The reaction of 1H-imidazole-4-carbohydrazides 1, which are conveniently 
accessible by treatment of the corresponding esters with NH2NH2·H2O, with 
isothiocyanates in refluxing EtOH led to thiosemicarbazides 4 in high yields (Scheme 
2). Whereas 4 in boiling aqueous NaOH yielded 1,2,4-triazole-5-thiones 5, the reaction 
in conc. H2SO4 at room temperature gave 5-amino-1,3,4-thiadiazoles 6. Similarly, the 
reaction of 1 with butylisocyanate led to semicarbazides 7, which under basic conditions 
cyclized to give 1,2,4-triazol-5-ones 3 (Scheme 3). Treatment of 1 with Ac2O yielded 
the diacylhydrazines 9 exclusively, and the alternative isomerization of 1 to imidazol-2-
ones was not observed (Scheme 4). It is important to note that in all these 
transformations the imidazole N-oxide residue is retained. Furthermore, it was shown 
that imidazole N-oxides bearing a 1,2,4-triazole-5-thione or 5-amino-1,3,4-thiadiazole 
substituent undergo the S-transfer reaction to give bis-heterocyclic imidazole-2-thiones 




1. Introduction. - Acid hydrazides (carbohydrazides) and the corresponding 
hydrazones are well known as a class of compounds with diverse biological activities 
[1]. Particularly important are derivatives bearing a heterocycle, and one of the best-
known examples is isoniazid (isonicotinohydrazide) [2]. Imidazole derived hydrazides 
were also reported to display biological activity [3], and the majority of reports remain 
to patents (e.g., ref. [4]). However, in most cases, N,N-disubstituted hydrazides were 
described, which are of limited interest with respect to their use as building blocks for 
new heterocyclic systems.  
The N-unsubstituted carbohydrazides are widely applied as unique building 
blocks for the synthesis of diverse five- and six-membered heterocycles such as 
pyrroles, pyrazoles, thiazolidines, 1,2,4-triazoles, phthalazines, pyrimidines, etc. [5]. A 
typical procedure for the preparation of unsubstituted hydrazides is the treatment of the 
corresponding carboxylic ester with NH2NH2·H2O [1][5]. In a recent publication we 
have reported on the application of this method for the preparation of diverse types of 
unsubstituted hydrazides containing in their structure the imidazole ring [6]. The 
precursors of 4-imidazoyl hydrazides 1 were the esters 2, available via condensation of 





In earlier papers, we presented the synthetic potential of the ‘nitrone-like’ 
fragment of 2-unsubstituted imidazole N-oxides [8]. The goal of the present study was 
the synthesis of new bis-heterocycles with the preserved imidazole N-oxide unit by 
exploration of the reactivity of the carbohydrazido group in compounds 1. In 
 4 
preliminary experiments it was shown that hydrazides 1 can be used for the preparation 
of bis-heterocycles [6]. To the best of our knowledge, there are no other bis-
heterocycles with the reactive N-oxide function known to date (cf. [6]). 
 
Results and Discussion. – As described earlier, imidazole N-oxides 1 with the 
hydrazido substituent of C(4) are stable, colorless, crystalline materials [6]. In contrast 
to the corresponding esters they did not undergo the thermal isomerization to imidazol-
2-ones. Even more surprisingly, they could neither be converted to the corresponding 
imidazole-2-thiones via the ‘sulfur-transfer reaction’ [8a] nor reduced to the parent 
system by treatment with Raney-Ni [8c]. 
It seems likely that these diminished reactivity of the N→O function is the result 
of a strong intramolecular H-bond [6][8d]. On the other hand, reactions with aldehydes 
and aliphatic ketones occurred smoothly yielding the expected hydrazones [6]. In 
addition, a preliminary experiment showed that thiosemicarbazide 4a obtained from 1a 
(R = PhCH2) and methyl isothiocyanate underwent the cyclocondensation yielding, 
depending on the reaction conditions, bis-heterocycles 5a or 6a. In analogy to 1a, 
derivatives 1b and 1c were also reacted with other isothiocyanates (R2 = Bu, Ph), and 
the thiosemicarbazides 4 were heated in a 2% aqueous solution of NaOH to give the 
triazole-3-thiones 5 (Scheme 2). In addition, the sterically crowded tert-
butylisothiocyanate was used for the reaction with 1a, and the expected 
thiosemicarbazide 4d was obtained in good yield as a crystalline material. However, the 
attempted cyclization of 4d under basic conditions was unsuccessful and the starting 
material was recovered in nearly quantitative yield. Apparently, in this case, steric 
hindrance resulting from the presence of the bulky tert-butyl group at the N-atom does 





The structure of the triazole-3-thiones 5 was indicated by the C=S absorption in 
the 13C-NMR spectra at 168 – 169 ppm. In addition, the unchanged N-oxide structure of 
the imidazole was confirmed by the characteristic 1H-NMR absorption of H–C(2) at 8.6 
– 8.1 ppm. 
The alternative course of the cyclocondensation was observed when 
thiosemicarbazides of type 4 were stirred in conc. H2SO4 at room temperature for one 
day. Under these conditions, the only products formed were 5-amino-1,3,4-thiadiazol-2-
yl-substituted imidazole N-oxides 6 (Scheme 2). Unexpectedly, the reactions carried out 
under these conditions with 4b and 4i, which were derived from phenylisothiocyanate, 
yielded 6b and 6e, respectively, bearing a phenylsulfonic acid residue (R2 = 4-
HO3SC6H4). It is very likely that these products result from the sulfonation of the 
intermediate 5-phenylamino-1,3,4-thiadizole derivatives formed after the initial 
cyclocondensation step2). Based on the comparison of the chemical shifts of H–C(2) in 
6b and in the analogous MeN and BuN derivatives 6a and 6c, respectively, a 
zwitterionic structure can be postulated for both arylsulfonic acids 6b and 6e (see 
Scheme 5). To the best of our knowledge, secondary sulfonation of 5-phenylamino-
1,3,4-thiadiazoles obtained from corresponding thiosemicarbazides in the presence of 
H2SO4 under similar reaction conditions (r.t.) has not been reported so far [12][13]. 
                                                          
2) The sulfonation of aniline with conc. H2SO4 at elevated temperatures is a well known 
process [9] and has been studied in detail by Khelevin [10]. A study of the thermolysis 
of diphenylammonium hydrogen sulfate leading to 4-(phenylamino)benzenesulfonic 
acid has bee published recently [11]. 
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Similarly to the reactions with isothiocyanates, hydrazides 1a and 1b reacted 
with butyl isocyanate in refluxing EtOH yielding semicarbazides 7a and 7b, 
respectively, as crystalline materials in high yields (Scheme 3). After isolation and 
purification, they were used for the synthesis of bis-heterocyclic 1,2,4-triazol-3-ones 





Transformation of hydrazides into 3-alkyl-1,3,4-oxadiazoles can be performed 
via cyclization of their N-acyl derivatives under acidic conditions [5]. In the case of 
hydrazides 1a and 1c, the acetylation performed with a slight excess of Ac2O in boiling 
EtOH afforded the expected N-acetyl derivatives 9 (Scheme 4). Apparently, this 
conversion is much faster than the alternative isomerization to the corresponding 
imidazol-2-ones reported as a typical reaction of 2-unsubstituted imidazole N-oxides by 
treatment with Ac2O [8b]. However, the attempted cyclocondensations of products 9 




In a series of reports we demonstrated that the treatment of 2-unsubstituted 
imidazole N-oxides with a cycloaliphatic thioketone, e.g., 2,2,4,4-
tetramethylcyclobutane-1,3-dithione (10) opens an easy access to imidazole-2-thiones 
[8a,c,e,f]. On the other hand, we found recently that the presence of a hydrazide group 
at C(4) inhibits the S-transfer reaction [6]. Having in hand bis-heterocyclic imdazole N-
 7 
oxides of type 5 and 6, the S-transfer with 10 was tested. In both cases (5g, 6e), the 




This result points out the influence of the intramolecular H-bond on the ‘nitrone-
like’ reactivity of the imidazole N-oxides 1. Whereas the strong H-bond in the 
hydrazides [6] causes reduced reactivity, there is no such H-bond present in the bis-
heterocyclic imidazole N-oxides 5 and 6, which easily enter a [2 + 3] cycloaddition with 
10. 
 
Conclusions. – The present study shows that imidazole carbohydrazides of type 
1, containing the N-oxide function, react with isothiocyanates, isocyanates, and Ac2O in 
a typical manner yielding the corresponding thiosemicarbazides 4, semicarbazides 7, 
and N-acetyl derivatives 9, respectively, in high yields. In the case of 
thiosemicarbazides, cyclizations to 1,2,4-triazole-3-thiones 5 and 2-amino-1,3,4-
thiadiazoles 6 were performed under basic and acidic conditions, correspondingly. 
Similarly, semicarbazides 7 were converted into 1,2,4-triazole-3-ones 8 in aqueous 
NaOH solution. In all these reactions, the N-oxide function in the imidazole ring was 
preserved. However, attempted acid-catalyzed cyclizations of 7 and 9 to the 
corresponding 3-amino- and 3-methyl-1,3,4-oxadiazoles, respectively, were 
unsuccessful.  
In contrast to hydrazides 1, which were shown not to undergo the S-transfer 
reaction upon treatment with the dithione 10 under standard conditions [6], bis-
heterocyclic imidazole N-oxides of type 5 and 6 smoothly undergo this reaction. 
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To the best of our knowledge, the elaborated protocol offers a unique route for 
the synthesis of bis-heterocyclic N-oxides, which cannot be prepared using an oxidative 
approach. This novel type of N-oxides may be of interest as a new group of ligands for 
coordination chemistry. Moreover, in a recent paper, derivatives of 5-amino-1,3,4-
thiadiazoles obtained from 5-methylimidazole-4-carbohydrazide according to the 
general method described in the present paper, displayed high anti-Toxoplasma gondi 
and antimicrobial activities [13]. 
 
 
The authors thank PD Dr. L. Bigler, University of Zurich, for recording of the 
HR-ESI-MS spectra. A. P. thanks for financial support within the project co-funded by 






1. General. M.p.: STUART SMP30; uncorrected. IR Spectra: NEXUS FT-IR 
spectrophotometer; in KBr; absorptions in cm–1. 1H- and 13C{1H}-NMR Spectra: Bruker 
Avance III 600, in (D6)DMSO, using solvent signals as reference; δ in ppm; coupling 
constants J in Hz; assignments of signals in 13C-NMR spectra accomplished on the basis 
of HMQC experiments. HR-ESI-MS: Finnigan MAT-95; HR-EI-MS: Bruker Esquire 
LC spectrometer.  
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2. Starting Materials. All solvents are commercially available and used as 
received. Hydrazides 1a – 1c were prepared from the corresponding esters by treatment 
with NH2NH2·H2O according to the previously described protocol [6].  
 
3. Synthesis of Thiosemicarbazides 4a – 4j and Semicarbazides 7a and 7b. 
General Procedure. A mixture of hydrazide 1 (1 mmol) and the corresponding 
isothiocyanate (1.1 mmol) or isocyanate (1.1 mmol) in EtOH (5 ml) was heated to 
reflux for 2 h. Then, the formed product was filtered off, washed with Et2O and 
crystallized from MeOH.  
1-{[(1-Benzyl-5-methyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
methylthiourea (4a) [6]. 
1-{[(1-Benzyl-5-methyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
phenylthiourea (4b): Yield: 0.347 g (91%). Colorless crystals. M.p. 200 – 204° (dec., 
MeOH). IR (KBr): 3295s (NH), 3127s, 1663vs (C=O), 1599vs, 1497m, 708m. 1H-NMR 
((D6)DMSO): 9.80 (br. s, NH); 8.72 (s, H–C(2’)); 7.48 – 7.12 (m, 10 arom. H); 5.26 (s, 
CH2); 2.45 (s, Me); two NH absorptions missing. 13C-NMR ((D6)DMSO): 178.2 (C=O); 
159.2 (C=S); 139.7, 135.9, 131.2, 121.3 (2 arom. C, C(4’), C(5’)); 126.7 (C(2’)); 129.5, 
128.7, 128.6, 127.7, 127.6, 125.3 (10 arom. CH); 48.7 (CH2); 9.8 (Me). HR-ESI-MS: 
404.1149 ([M+Na]+, C19H19N5NaO2S; calc. 404.1152); 382.1329 ([M+H]+, 
C19H20N5O2S; calc. 382.1332).  
1-{[(1-Benzyl-5-methyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
butylthiourea (4c). Yield: 0.343 g (95%). Colorless crystals. M.p. 204 – 207° (MeOH). 
IR (KBr): 3243m (NH), 2955s, 1661vs (C=O), 1598vs, 1552m, 1456m, 737m. 1H-NMR 
((D6)DMSO): 12.41, 9.31 (2 br. s, 2 NH); 8.72 (s, H–C(2’)); 8.03 (br. s, NH); 7.42 – 
7.25 (m, 5 arom. H); 5.25 (s, CH2); 3.40 (q, J = 6.6, CH2N); 2.43 (s, Me); 1.49 – 1.44, 
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1.28 – 1.22 (2 m, 2 CH2); 0.86 (t, J = 7.2, Me). 13C-NMR ((D6)DMSO): 181.7 (C=O); 
159.6 (C=S); 135.9, 131.2, 121.3 (1 arom. C, C(4’), C(5’)); 126.7 (C(2’)); 129.5, 128.7, 
127.7 (5 arom. CH); 48.7 (PhCH2); 43.9 (CH2N); 31.3, 19.9 (2 CH2); 14.2 (Me); 9.8 
(MeC(2’)). HR-ESI-MS: 384.1467 ([M+Na]+, C17H23N5NaO2S; calc. 384.1465); 
362.1643 ([M+H]+, C17H24N5O2S; calc. 362.1645).  
1-{[(1-Benzyl-5-methyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-(tert-
butyl)thiourea (4d). Yield: 0.235 g (65%). Colorless crystals. M.p. 201 – 203° (MeOH). 
IR (KBr): 3235m (NH), 3088s, 1668vs (C=O), 1599vs, 1541m, 1362m, 709m.  
1H-NMR ((D6)DMSO): 9.51 (br. s, NH); 8.67 (s, H–C(2’)); 7.41 – 7.25 (m, 5 arom. H); 
5.24 (s, CH2); 2.43 (s, Me); 1.44 (s, Me3C); two NH absorptions missing. 13C-NMR 
((D6)DMSO): 178.9 (C=O); 159.8 (C=S); 135.8, 131.1, 120.9 (1 arom. C, C(4’), C(5’)); 
126.7 (C(2’)); 129.4, 128.6, 127.7 (5 arom. CH); 53.2 (Me3C); 48.7 (CH2); 29.1 (3 
Me3C); 9.8 (MeC(2’)). HR-ESI-MS: 384.1469 ([M+Na]+, C17H23N5NaO2S; calc. 
384.1465); 362.1646 ([M+H]+, C17H24N5O2S; calc. 362.1645).  
1-{[(1,5-Dimethyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
methylthiourea (4e). Yield: 0.173 g (71%). Colorless crystals. M.p. 229 – 231º (MeOH). 
IR (KBr): 3160s, 2974s, 1638vs (C=O), 1602vs, 1485s, 1285m, 606m. 1H-NMR 
((D6)DMSO): 9.35 (br. s, NH); 8.48 (s, H–C(2’)); 8.01 (br. s, NH); 3.58 (s, imidazole 
Me); 2.85 (d, J = 4.1, MeN); 2.48 (s, Me); one NH absorption missing. 13C-NMR 
((D6)DMSO): 182.6 (C=O); 159.8 (C=S); 131.8, 120.7 (C(4’), C(5’)); 126.8 (C(2’)); 
32.4 (MeN(1’)); 31.4 (MeN); 9.5 (MeC(2’)). HR-ESI-MS: 266.0682 ([M+Na]+, 
C8H13N5NaO2S; calc. 266.0682); 244.0859 ([M+H]+, C8H14N5O2S; calc. 244.0863).  
1-{[(1,5-Dimethyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
phenylthiourea (4f). Yield: 0.262 g (86%). Colorless crystals. M.p. 223 – 225º (MeOH). 
IR (KBr): 3245m (NH), 3093s, 3036s, 1667vs (C=O), 1600vs, 1497s, 1321s, 760m. 1H-
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NMR ((D6)DMSO): 9.79 (br. s, NH); 8.48 (s, H–C(2’)); 7.50 – 7.11 (m, 5 arom. H); 
3.58 (s, MeN); 2.50 (s, Me; overlaps with DMSO signal); two NH absorptions missing. 
13C-NMR ((D6)DMSO): 179.0 (C=O); 160.8 (C=S); 139.8, 131.6, 120.7 (1 arom. C, 
C(4’), C(5’)); 128.8, 128.6, 125.1 (5 arom. CH); 126.8 (C(2’)); 32.4 (MeN); 9.5 
(MeC(2’)). HR-ESI-MS: 328.0835 ([M+Na]+, C13H15N5NaO2S; calc. 328.0839); 
306.1013 ([M+H]+, C13H16N5O2S; calc. 306.1019).  
1-{[(1,5-Dimethyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
butylthiourea (4g). Yield: 0.262 g (92%). Colorless crystals. M.p. 208 – 210º (MeOH). 
IR (KBr): 3189s, 2957s, 1640vs (C=O), 1599vs, 1483s, 1277m, 616m. 1H-NMR 
((D6)DMSO): 12.44, 9.30 (2 br. s, 2 NH); 8.47 (s, H–C(2’)); 8.01 (br. s, NH); 3.58 (s, 
MeN); 3.40 (q, J = 6.6, CH2N); 2.48 (s, Me); 1.49 – 1.44, 1.29 – 1.22 (2 m, 2 CH2); 0.87 
(t, J = 7.2, Me). 13C-NMR ((D6)DMSO): 181.7 (C=O); 159.5 (C=S); 131.7, 120.7 
(C(4’), C(5’)); 126.8 (C(2’)); 43.9 (CH2N); 31.4 (MeN); 31.3, 19.9 (2 CH2); 14.2 (Me); 
9.5 (MeC(2’)). HR-ESI-MS: 308.1151 ([M+Na]+, C11H19N5NaO2S; calc. 308.1152); 
286.1329 ([M+H]+, C11H20N5O2S; calc. 286.1332).  
1-{[(1-Cyclohexyl-5-methyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
methylthiourea (4h). Yield: 0.258 g (83%). Colorless crystals. M.p. 207 – 211º (MeOH). 
IR (KBr): 3250s (NH), 3139s, 1664vs (C=O), 1596vs, 1552m, 1495m, 1259m. 1H-NMR 
((D6)DMSO): 12.45, 9.35 (2 br. s, 2 NH); 8.72 (s, H–C(2’)); 8.00 (br. s, NH); 4.12 – 
4.07 (m, CH); 2.85 (d, J = 4.4, MeN); 2.55 (s, Me); 1.92 – 1.79 (m, 4 cyclohexyl H); 
1.67 – 1.60 (m, 3 cyclohexyl H); 1.44 – 1.38 (m, 2 cyclohexyl H); 1.21 – 1.13 (m, 1 
cyclohexyl H). 13C-NMR ((D6)DMSO): 182.6 (C=O); 159.9 (C=S); 130.7, 120.3 (C(4’), 
C(5’)); 124.5 (C(2’)); 55.1 (CH); 33.0, 25.3, 25.0 (5 cyclohexyl CH2); 31.4 (MeN); 9.5 
(MeC(2’)). HR-ESI-MS: 334.1306 ([M+Na]+, C13H21N5NaO2S; calc. 334.1308); 
312.1488 ([M+H]+, C13H22N5O2S; calc. 312.1489).  
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1-{[(1-Cyclohexyl-5-methyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
phenylthiourea (4i). Yield: 0.332 g (89%). Colorless crystals. M.p. 174 – 176° (MeOH). 
IR (KBr): 3231s (NH), 3139s, 2934s, 1675vs (C=O), 1600vs, 1497m, 1257m. 1H-NMR 
((D6)DMSO): 9.81 (br. s, NH); 8.73 (s, H–C(2’)); 7.50 – 7.12 (m, 5 arom. H); 4.12 – 
4.07 (m, CH); 2.57 (s, Me); 1.93 – 1.80 (m, 4 cyclohexyl H); 1.67 – 1.61 (m, 3 
cyclohexyl H); 1.45 – 1.38 (m, 2 cyclohexyl H); 1.22 – 1.14 (m, 1 cyclohexyl H); two 
NH absorptions missing. 13C-NMR ((D6)DMSO): 172.4 (C=O); 156.2 (C=S); 139.7, 
130.6, 120.3 (1 arom. C, C(4’), C(5’)); 129.4, 129.1, 128.6 (5 arom. CH); 124.4 (C(2’)); 
55.1 (CH); 33.0, 25.4, 25.0 (5 cyclohexyl CH2); 9.5 (MeC(2’)). HR-ESI-MS: 396.1469 
([M+Na]+, C18H23N5NaO2S; calc. 396.1465); 374.1649 ([M+H]+, C18H24N5O2S; calc. 
374.1645).  
1-{[(1-Cyclohexyl-5-methyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
butylthiourea (4j). Yield: 0.318 g (90%). Colorless crystals. M.p. 176 – 180º (MeOH). 
IR (KBr): 3302s (NH), 3143s, 2934s, 1681vs (C=O), 1604vs, 1545m, 1265m. 1H-NMR 
((D6)DMSO): 12.48, 9.26 (2 br. s, 2 NH); 8.72 (s, H–C(2’)); 8.02 (br. s, NH); 4.11 – 
4.07 (m, CH); 3.43 – 3.38 (m, CH2N); 2.55 (s, Me); 1.92 – 1.79 (m, 4 cyclohexyl H); 
1.67 – 1.60 (m, 3 cyclohexyl H); 1.49 – 1.38 (m, 2 cyclohexyl H, butyl CH2); 1.28 – 
1.15 (m, 1 cyclohexyl H, butyl CH2); 0.87 (t, J = 7.6, Me). 13C-NMR ((D6)DMSO): 
181.7 (C=O); 159.8 (C=S); 130.6, 120.3 (C(4’), C(5’)); 124.4 (C(2’)); 55.0 (CH); 43.9 
(CH2N); 33.0, 25.3, 25.0 (5 cyclohexyl CH2); 31.3, 19.9 (2 butyl CH2); 14.2 (Me); 9.5 
(MeC(2’)). HR-ESI-MS: 376.1777 ([M+Na]+, C16H27N5NaO2S; calc. 376.1778); 
354.1955 ([M+H]+, C16H28N5O2S; calc. 354.1958).  
1-{[(1-Benzyl-5-methyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-
butylylurea (7a). Yield: 0.338 g (98%). Colorless crystals. M.p. 201 – 205º (MeOH). IR 
(KBr): 3304s (NH), 3105m, 2960m, 1656vs (C=O), 1603s, 1544m. 1H-NMR 
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((D6)DMSO): 12.08 (br. s, NH); 8.67 (s, H–C(2’)); 7.41 – 7.23 (m, 5 arom. H); 7.94, 
6.42 (2 br. s, 2 NH); 5.24 (s, CH2); 3.01 (q, J = 7.0, CH2N); 2.42 (s, Me); 1.38 – 1.34, 
1.29 – 1.22 (2 m, 2 CH2); 0.86 (t, J = 7.0, Me). 13C-NMR ((D6)DMSO): 159.5, 158.0 (2 
C=O); 135.9, 131.0, 121.3 (1 arom. C, C(4’), C(5’)); 126.8 (C(2’)); 129.4, 128.6, 127.6 
(5 arom. CH); 48.7 (PhCH2); 39.4 (CH2N); 32.4, 19.9 (2 CH2); 14.2 (Me); 9.7 
(MeC(2’)). HR-ESI-MS: 368.1697 ([M+Na]+, C17H23N5NaO3; calc. 368.1693); 
346.1875 ([M+H]+, C17H24N5O3; calc. 346.1874).  
1-{[(1,5-Dimethyl-3-oxido-1H-imidazolium-4-yl)carbonyl]amino}-3-butylurea 
(7b). Yield: 0.256 g (95%). Colorless crystals. M.p. 190 – 193º (MeOH). IR (KBr): 
3308vs, 3132m, 2957s, 1644vs (C=O), 1602s, 1534s, 1254m, 608m. 1H-NMR 
((D6)DMSO): 12.10 (br. s, NH); 8.44 (s, H–C(2’)); 7.93, 6.39 (2 br. s, 2 NH); 3.56 (s, 
MeN); 3.00 (q, J = 5.8, CH2N); 2.47 (s, Me); 1.39 – 1.34, 1.29 – 1.23 (2 m, 2 CH2); 0.87 
(t, J = 7.0, Me). 13C-NMR ((D6)DMSO): 159.5, 158.0 (2 C=O); 131.4, 120.7 (C(4’), 
C(5’)); 126.8 (C(2’)); 39.4 (CH2N); 32.4 (MeN); 32.3, 19.9 (2 CH2); 14.2 (Me); 9.4 
(MeC(2’)). HR-ESI-MS: 292.1383 ([M+Na]+, C11H19N5NaO3; calc. 292.1380); 
270.1560 ([M+H]+, C11H20N5O3; calc. 270.1561).  
4. Synthesis of 1,2,4-Triazole-3-thiones 5. General Procedure. A mixture of 
thiosemicarbazide 4 (1 mmol) and a 2% aq. soln. of NaOH (5 ml) was heated to reflux 
for 2 h. Then, the soln. was neutralized with AcOH and the formed precipitate was 
filtered off and crystallized from MeOH.  
1-Benzyl-4-(4,5-dihydro-4-methyl-5-thioxo-1H-1,2,4-triazol-3-yl)-5-methyl-1H-
imidazole 3-Oxide (5a) [6]. 
1-Benzyl-4-(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)-5-methyl-1H-
imidazole 3-Oxide (5b). Yield: 0.192 g (53%). Colorless crystals. M.p. 262 – 264º (dec. 
MeOH). IR (KBr): 3110s, 3044m, 1497s, 1319m, 688m. 1H-NMR ((D6)DMSO): 8.35 (s, 
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H–C(2)); 7.47 – 7.28 (m, 10 arom. H); 5.11 (s, CH2N); 1.92 (s, Me); NH absorption 
missing. 13C-NMR ((D6)DMSO): 168.8 (C=S); 141.4 (triazole C(3)); 134.3, 128.8, 
136.2, 117.6 (2 arom. C, imidazole C(4), C(5)); 129.3, 129.2, 128.4, 127.7, 127.2, 126.8 
(10 arom. CH); 126.2 (imidazole C(2)); 48.8 (CH2N); 8.9 (Me). HR-ESI-MS: 386.1041 
([M+Na]+, C19H17N5NaOS; calc. 386.1046); 364.1221 ([M+H]+, C19H18N5OS; calc. 
364.1227). 
1-Benzyl-4-(4,5-dihydro-4-butyl-5-thioxo-1H-1,2,4-triazol-3-yl)-5-methyl-1H-
imidazole 3-Oxide (5c). Yield: 0.240 g (70%). Colorless crystals. M.p. 256–258º 
(MeOH). IR (KBr): 3129m, 2930m, 1455m, 1294m, 730m. 1H-NMR ((D6)DMSO): 8.60 
(s, H–C(2)); 7.41 – 7.25 (m, 5 arom. H); 5.26 (s, CH2N); 4.12 (t, J = 6.8, CH2N); 2.08 
(s, Me); 1.45 – 1.40 (m, CH2); 1.04 – 0.98 (m, CH2); 0.67 (t, J = 6.8, Me); NH 
absorption missing. 13C-NMR ((D6)DMSO): 167.9 (C=S); 141.7 (triazole C(3)); 136.1, 
128.4, 118.5 (1 arom. C, imidazole C(4), C(5)); 129.4, 128.6, 127.6 (5 arom. CH); 126.7 
(imidazole C(2)); 49.2 (CH2N); 44.0 (butyl CH2N); 30.1, 19.4 (2 butyl CH2); 13.7 (butyl 
Me); 9.1 (Me). HR-ESI-MS: 366.1359 ([M+Na]+, C17H21N5NaOS; calc. 366.1359); 
344.1537 ([M+H]+, C17H22N5OS; calc. 344.1540). 
1,5-Dimethyl-4-(4,5-dihydro-4-methyl-5-thioxo-1H-1,2,4-triazol-3-yl)-1H-
imidazole 3-Oxide (5d). Yield: 0.144 g (64%). Colorless crystals. M.p. 321 – 323º 
(MeOH). IR (KBr): 3147vs (NH), 1515m, 1455m, 1329m, 929m. 1H-NMR 
((D6)DMSO): 8.31 (s, H–C(2)); 3.58, 3.44 2(s, 2 MeN); 2.17 (s, Me); NH absorption 
missing. 13C-NMR ((D6)DMSO): 168.2 (C=S); 142.3 (triazole C(3)); 128.1, 118.7 
(imidazole C(4), C(5)); 126.2 (imidazole C(2)); 32.7, 31.4 (2 MeN); 9.1 (Me). HR-ESI-
MS: 248.0574 ([M+Na]+, C8H11N5NaOS; calc. 248.0577); 226.0755 ([M+H]+, 
C8H12N5OS; calc. 226.0757).  
 15 
1,5-Dimethyl-4-(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)-1H-
imidazole 3-Oxide (5e). Yield: 0.155 g (54%). Colorless crystals. M.p. 270 – 274º (dec. 
MeOH). IR (KBr): 3156vs (NH), 1506m, 1497s, 1326m, 694m. 1H-NMR ((D6)DMSO): 
8.14 (s, H–C(2)); 7.51 – 7.38 (m, 5 arom. H); 3.45 (s, MeN); 2.09 (s, Me); NH 
absorption missing. 13C-NMR ((D6)DMSO): 169.0 (C=S); 141.7 (triazole C(3)); 136.9, 
128.9, 117.1 (1 arom. C, imidazole C(4), C(5)); 129.4, 129.1, 127.8 (5 arom. CH); 126.2 
(imidazole C(2)); 32.6 (MeN); 8.7 (Me). HR-ESI-MS: 310.0733 ([M+Na]+, 
C13H13N5NaOS; calc. 310.0733); 288.0911 ([M+H]+, C13H14N5OS; calc. 288.0914).  
1,5-Dimethyl-4-(4-butyl-4,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-yl)-1H-
imidazole 3-Oxide (5f). Yield: 0.143 g (50%). Colorless crystals. M.p. 240 – 242º 
(MeOH). IR (KBr): 3162s (NH), 2953s, 1570m, 1449m, 1348m, 1295m, 926m. 1H-
NMR ((D6)DMSO): 8.38 (s, H–C(2)); 4.14 (t, J = 7.7, CH2N); 3.59 (s, MeN); 2.17 (s, 
Me); 1.51 – 1.46, 1.12 – 1.05 (2m, 2 CH2); 0.74 (t, J = 7.7, Me); NH absorption missing. 
13C-NMR ((D6)DMSO): 167.9 (C=S); 142.2 (triazole C(3)); 128.8, 117.5 (imidazole 
C(4), C(5)); 126.7 (imidazole C(2)); 44.1 (CH2N); 32.8 (MeN); 30.0, 19.5 (2 CH2); 
13.7, 8.9 (2 Me). HR-ESI-MS: 290.1042 ([M+Na]+, C11H17N5NaOS; calc. 290.1046); 
268.1225  ([M+H]+, C11H18N5OS; calc. 268.1227).  
1-Cyclohexyl-4-(4,5-dihydro-4-methyl-5-thioxo-1H-1,2,4-triazol-3-yl)-5-methyl-
1H-imidazole 3-Oxide (5g). Yield: 0.240 g (82%). Colorless crystals. M.p. 212 – 216º 
(MeOH). IR (KBr): 3115s (NH), 2941s, 1559m, 1418m, 1324m. 1H-NMR ((D6)DMSO): 
8.49 (s, H–C(2)); 4.05 – 4.00 (m, CH); 3.42 (s, MeN); 2.20 (s, Me); 1.97 – 1.80 (m, 4 
cyclohexyl H); 1.69 – 1.62 (m, 3 cyclohexyl H); 1.45 – 1.38 (m, 2 cyclohexyl H); 1.23 – 
1.14 (m, 1 cyclohexyl H); NH absorption missing. 13C-NMR ((D6)DMSO): 168.3 
(C=S); 142.1 (triazole C(3)); 126.7, 118.7 (imidazole C(4), C(5)); 123.6 (imidazole 
C(2)); 55.5 (CH); 33.2 (MeN); 31.4, 25.4, 23.1 (5 cyclohexyl CH2); 9.2 (Me). HR-ESI-
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MS: 316.1200 ([M+Na]+, C13H19N5NaOS; calc. 316.1203); 294.1379  ([M+H]+, 
C13H20N5OS; calc. 294.1383).  
1-Cyclohexyl-4-(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)-5-methyl-
1H-imidazole 3-Oxide (5h). Yield: 0.185 g (52%). Colorless crystals. M.p. 282 – 284º 
(MeOH). IR (KBr): 3231m (NH), 2936m, 1601m, 1497m, 1320m. 1H-NMR 
((D6)DMSO): 8.34 (s, H–C(2)); 7.45 – 7.37 (m, 5 arom. H); 3.92 – 3.85 (m, CH); 2.07 
(s, Me); 1.79 – 1.74 (m, 4 cyclohexyl H); 1.62 – 1.49 (m, 3 cyclohexyl H); 1.37 – 1.30 
(m, 2 cyclohexyl H); 1.15 – 1.12 (m, 1 cyclohexyl H); NH absorption missing. 13C-
NMR ((D6)DMSO): 168.9 (C=S); 141.6 (triazole C(3)); 134.1, 126.1, 118.4 (1 arom. C, 
imidazole C(4), C(5)); 129.3, 129.0, 127.7 (5 arom. CH); 123.6 (imidazole C(2)); 55.4 
(CH); 33.0, 25.3, 24.9 (5 cyclohexyl CH2); 8.9 (Me). HR-ESI-MS: 378.1361 ([M+Na]+, 
C18H21N5NaOS; calc. 378.1359); 356.1541 ([M+H]+, C18H22N5OS; calc. 356.1540).  
1-Cyclohexyl-4-(4-butyl-4,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-yl)-5-methyl-
1H-imidazole 3-Oxide (5i). Yield: 0.251 g (75%). Colorless crystals. M.p. 248–250º 
(MeOH). IR (KBr): 3066m, 2936m, 1356m, 1295m. 1H-NMR ((D6)DMSO): 8.55 (s, H–
C(2)); 4.12 (t, J = 6.8, CH2N); 4.07 – 4.02 (m, CH); 2.20 (s, Me); 1.95 – 1.81 (m, 4 
cyclohexyl H); 1.69 – 1.62 (m, 3 cyclohexyl H); 1.48 – 1.38 (m, 2 cyclohexyl H, butyl 
CH2); 1.22 – 1.17 (m, 1 cyclohexyl H); 1.07 – 1.01 (m, butyl CH2); 0.69 (t, J = 6.8, Me); 
NH absorption missing. 13C-NMR ((D6)DMSO): 167.9 (C=S); 141.9 (triazole C(3)); 
123.1, 118.4 (imidazole C(4), C(5)); 123.9 (imidazole C(2)); 55.6 (CH); 43.7 (CH2N); 
33.2, 25.4, 25.0 (5 cyclohexyl CH2); 30.0, 19.3 (2 butyl CH2); 13.6, 9.0 (2 Me). HR- 
HR-ESI-MS: 358.1677 ([M+Na]+, C16H25N5NaOS; calc. 358.1672); 336.1856 ([M+H]+, 
C16H26N5OS; calc. 336.1853).  
5. Synthesis of 1,3,4-Thiadiazoles 6. General procedure. A soln. of 
thiosemicarbazide 4 (1 mmol) in conc. H2SO4 (5 ml) was kept at r.t. for 1 d. After 
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neutralization of the soln. with diluted NH4OH, the solid product was filtered off, dried, 
and crystallized from MeOH. 
1-Benzyl-5-methyl-4-(5-methylamino-1,3,4-thiadiazol-2-yl)-1H-imidazole 3-
Oxide (6a) [6].  
1-Benzyl-5-methyl-4-[5-(4-sulfophenyl)amino]-1,3,4-thiadiazol-2-yl)-1H-
imidazole 3-Oxide (6b). Yield: 0.211 g (58%). Yellowish crystals. M.p. 300 – 303º 
(dec., MeOH). IR (KBr): 3400–2800m (br), 3124m, 3064m, 1509s, 1176m (br), 1034m, 
708m. 1H-NMR ((D6)DMSO): 10.34 (br. s, NH); 8.66 (s, H–C(2)); 7.60, 7.57 (AA’BB’ , 
JAB = 8.4, 4 arom. H); 7.42 – 7.28 (m, 5 arom. H); 5.29 (s, CH2); 2.56 (s, Me). 13C-NMR 
((D6)DMSO): 164.4, 146.4 (thiadiazole C(2), C(5)); 142.1, 141.4, 136.1, 122.7, 116.6 (3 
arom. C, imidazole C(4), C(5)); 129.4, 128.6, 127.7, 127.0, 125.0 (9 arom. CH); 125.6 
(imidazole C(2)); 49.0 (CH2); 10.2 (Me). HR-ESI-MS: 488.0432 ([M–1+2 Na]+, 
C19H16N5Na2O4S2; calc. 488.0434); 466.0610 ([M+Na]+, C19H17N5NaO4S2; calc. 
466.0614); 444.0791 ([M+H]+, C19H18N5O4S2; calc. 444.0795).  
1-Benzyl-5-methyl-4-(5-butylamino-1,3,4-thiadiazol-2-yl)-1H-imidazole 3-Oxide 
(6c). Yield: 0.209 g (61%). Yellowish crystals. M.p. 206 – 208º (dec., MeOH). IR 
(KBr): 3185m, 3068m, 2958s, 1576s, 1454m, 748m. 1H-NMR ((D6)DMSO): 8.57 (s, H–
C(2)); 7.58 (br. s, NH); 7.41 – 7.26 (m, 5 arom. H); 5.24 (s, PhCH2); 3.34 – 3.23 (m, 
CH2N); 2.49 (s, Me); 1.59 – 1.54 (m, CH2); 1.39 – 1.33 (m, CH2); 0.90 (t, J = 7.6, Me). 
13C-NMR ((D6)DMSO): 169.2, 144.4 (thiadiazole C(2), C(5)); 136.3, 124.0, 123.0 (1 
arom. C, imidazole C(4), C(5)); 129.4, 128.5, 127.6 (5 arom. CH); 125.3 (imidazole 
C(2)); 48.9 (PhCH2); 44.9 (CH2N); 31.2, 20.1 (2 CH2); 14.1, 10.1 (2 Me). HR-ESI-MS: 
366.1361 ([M+Na]+, C17H21N5NaOS; calc. 366.1359); 344.1541 ([M+H]+, C17H22N5OS; 
calc. 344.1540).  
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1,5-Dimethyl-4-(5-methylamino-1,3,4-thiadiazol-2-yl)-1H-imidazole 3-Oxide 
(6d). Yield: 0.207 g (92%). Yellowish crystals. M.p. 228 – 230º (dec., MeOH). IR 
(KBr): 3375s (NH), 3120s, 2941s, 1541m, 1404m, 1097m, 1033m, 604m. 1H-NMR 
((D6)DMSO): 8.37 (s, H–C(2)); 7.55 (br. s, NH); 3.59 (s, imidazole MeN); 2.89 (br. s, 
MeN); 2.54 (s, Me). 13C-NMR ((D6)DMSO): 169.8, 144.8 (thiadiazole C(2), C(5)); 
125.4 (imidazole C(2)); 124.5, 122.3 (imidazole C(4), C(5)); 32.5, 31.6 (2 MeN); 9.8 
(Me). HR-ESI-MS: 248.0578 ([M+Na]+, C8H11N5NaOS; calc. 248.0577); 226.0760  
([M+H]+, C8H12N5OS; calc. 226.0757).  
1-Cyclohexyl-5-methyl-4-[5-(4-sulfophenyl)amino]-1,3,4-thiadiazol-2-yl)-1H-
imidazole 3-Oxide (6e). Yield: 0.249 g (70%). Colorless crystals. M.p. 310 – 312º (dec., 
MeOH). IR (KBr): 3400–2650m (br), 3385s (NH), 3227s, 3038s, 1420s (br), 1090s (br), 
613m. 1H-NMR ((D6)DMSO): 10.29 (br. s, NH); 8.65 (s, H–C(2)); 7.60, 7.56 (AA’BB’, 
JAB = 8.4, 4 arom. H); 4.14 – 4.09 (m, CH); 2.68 (s, Me); 1.99 – 1.81 (m, 4 cyclohexyl 
H); 1.68 – 1.63 (m, 3 cyclohexyl H); 1.47 – 1.41 (m, 2 cyclohexyl H); 1.24 – 1.21 (m, 1 
cyclohexyl H). 13C-NMR ((D6)DMSO): 164.4, 146.7 (thiadiazole C(2), C(5)); 142.2, 
116.6 (2 arom. C); 141.4, 127.0 (4 arom. CH); 124.2 (imidazole C(2)); 123.1, 121.6 
(imidazole C(4), C(5)); 55.3 (CH); 33.1, 25.4, 25.0 (5 cyclohexyl CH2); 9.9 (Me). HR-
ESI-MS: 458.0926 ([M+Na]+, C18H21N5NaO4S2; calc. 458.0927); 436.1110 ([M+H]+, 
C18H22N5O4S2; calc. 436.1108).  
6. Synthesis of 1,2,4-Triazole-3-ones 8. General procedure. A mixture of 
semicarbazide 7 (1 mmol) and a 2% aq. soln. of NaOH (5 ml) was heated to reflux for 8 
h. Then, the soln. was neutralized with AcOH, the formed precipitate was filtered off, 
and crystallized from MeOH.  
1-Benzyl-4-(4-butyl-4,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-5-methyl-1H-
imidazole 3-Oxide (8a). Yield: 0.216 g (66%). Colorless crystals. M.p. 224 – 228º 
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(MeOH). IR (KBr): 3115m, 2938m, 1705vs (C=O), 1558m, 1416m, 734m. 1H-NMR 
((D6)DMSO): 8.55 (s, H–C(2)); 7.41 – 7.24 (m, 5 arom. H); 5.23 (s, PhCH2); 3.73 (t, J = 
6.8, CH2N); 2.08 (s, Me); 1.58 (br. s, NH); 1.37 – 1.32, 1.06 – 1.00 (2m, 2 CH2); 0.68 (t, 
J = 7.7, Me). 13C-NMR ((D6)DMSO): 155.4 (C=O); 137.4, 136.3, 127.8, 119.8 (1 arom. 
C, imidazole C(4), C(5), triazole C(3)); 129.4, 128.6, 127.6 (5 arom. CH); 126.3 
(imidazole C(2)); 49.1 (PhCH2); 41.0 (CH2N); 30.7, 19.4 (2 CH2); 13.6, 9.1 (2 Me). 
HR-ESI-MS: 350.1589 ([M+Na]+, C17H21N5NaO2; calc. 350.1588), 328.1771 ([M+H]+, 
C17H22N5O2; calc. 328.1768).  
4-(4-Butyl-4,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-1,5-dimethyl-1H-imidazole 
3-Oxide (8b). Yield: 0.176 g (70%). Colorless crystals. M.p. 214 – 216º (MeOH). IR 
(KBr): 3409vs (NH), 1698vs (C=O), 1559vs, 1410s, 649m. 1H-NMR ((D6)DMSO): 8.33 
(s, H–C(2)); 3.71 (q, J = 7.0, CH2N); 3.58 (s, MeN); 2.16 (s, Me); 1.64 (br. s, NH); 1.39 
– 1.35, 1.10 – 1.06 (2m, 2 CH2); 0.74 (t, J = 7.4, Me). 13C-NMR ((D6)DMSO): 155.6 
(C=O); 137.4, 128.2, 118.8 (imidazole C(4), C(5), triazole C(3)); 126.4 (imidazole 
C(2)); 41.1 (CH2N); 32.7 (MeN); 32.7, 19.5 (2 CH2); 13.7, 8.9 (2 Me). HR-ESI-MS: 
290.1012 ([M+K]+, C11H17KN5O2; calc. 290.1014), 274.1273 ([M+Na]+, 
C11H17N5NaO2; calc. 274.1275), 252.1451 ([M+H]+, C11H18N5O2; calc. 252.1455). 
7. Synthesis of N-Acetylhydrazides 9. General procedure. A mixture of 
hydrazide 1 (1 mmol) and Ac2O (1.1 mmol) in EtOH (5 ml) was heated to reflux for 2 h. 
The formed product was then filtered off, washed with Et2O, and crystallized from 
MeOH.  
N'-Acetyl-1-benzyl-5-methyl-3-oxido-1H-imidazolium-4-carbohydrazide (9a). 
Yield: 1.251 g (87%). Colorless crystals. M.p. 164 − 166º (MeOH). IR (KBr): 3119s, 
1663vs (C=O), 1601vs, 1497m, 709m. 1H-NMR ((D6)DMSO): 12.65, 10.26 (2 br. s, 2 
NH); 8.68 (s, H−C(2)); 7.41 − 7.23 (m, 5 arom. H); 5.24 (s, CH2); 2.42, 1.90 (2s, 2 Me). 
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13C-NMR ((D6)DMSO): 167.3, 159.7 (2 C=O); 135.6, 131.2, 120.8 (1 arom. C, C(4), 
C(5)); 129.5, 128.6, 127.6 (5 arom. CH); 126.9 (C(2)); 48.7 (CH2); 20.9, 9.6 (2 Me). 
HR-ESI-MS: 311.1118 ([M+Na]+, C14H16N4NaO3; calc. 311.1115); 289.1297 ([M+H]+, 
C14H17N4O3; calc. 289.1295).  
N'-Acetyl-1-cyclohexyl-5-methyl-3-oxido-1H-imidazolium-4-carbohydrazide 
(9b): Yield: 0.246 g (88%). Colorless crystals. M.p. 184−188º (MeOH). IR (KBr): 
3247s (NH), 2937s, 1654vs (C=O), 1601vs, 1418m, 1047m. 1H-NMR ((D6)DMSO): 
12.61 (br. s, NH); 8.68 (s, H−C(2)); 4.10–4.03 (m, CH); 2.55 (s, Me); 1.93–1.78 (m, 4 
cyclohexyl H, Me); 1.66–1.59 (m, 3 cyclohexyl H); 1.43–1.36 (m, 2 cyclohexyl H); 
1.20–1.13 (m, 1 cyclohexyl H). 13C-NMR ((D6)DMSO): 168.6, 158.0 (2 C=O); 130.7, 
119.8 (C(4), C(5)); 124.5 (C(2)); 55.1 (CH); 33.0, 25.3, 24.9 (5 cyclohexyl CH2); 20.9, 
9.4 (2 Me). HR-ESI-MS: 303.14267 ([M+Na]+, C13H20N4NaO3; calc. 303.1428); 
281.1607  ([M+H]+, C13H21N4O3; calc. 281.1608).  
8. Synthesis of 1H-Imidazole-2-thiones 11. General Procedure. To a 
magnetically stirred soln. of 1H-imidazole N-oxide 5g or 6e (1 mmol) in CH2Cl2 (1 ml), 
a soln. of 2,2,4,4-tetramethylcyclobutane-1,3-dithione (10, 0.6 mmol) in CH2Cl2 (1 ml) 
was added dropwise. The addition was complete after ca. 10 min, and stirring was 
continued for 48 h, while a precipitate was formed. Then, the solvent was removed 
under reduced pressure, the resulting solid was washed with hexane, and filtered. The 
crude product was recrystallized from MeOH.  
1-Cyclohexyl-4-(4,5-dihydro-4-methyl-5-thioxo-1H-1,2,4-triazol-3-yl)-5-methyl-
1H-imidazole-2(3H)-thione (11a). Yield: 0.250 g (81%). Colorless crystals. M.p. 276 – 
278º (MeOH). IR (KBr): 3092s, 2935s, 1560m, 1500m, 1416m, 1348m. 1H-NMR 
((D6)DMSO): 3.72 (s, MeN); 3.35 – 3.29 (m, CH); 2.33 (s, Me); 1.83 – 1.64 (m, 6 
cyclohexyl H); 1.36 – 1.16 (m, 4 cyclohexyl H); NH absorption missing. 13C-NMR 
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((D6)DMSO): 171.6, 163.2 (2 C=S); 141.2 (triazole C(3)); 126.3, 116.5 (imidazole C(4), 
C(5)); 55.4 (CH); 31.7 (MeN); 26.3, 25.8, 21.9 (5 cyclohexyl CH2); 11.9 (Me). HR-ESI-
MS: 332.0973 ([M+Na]+, C13H19N5NaS2; calc. 332.0974), 310.1150 ([M+H]+, 
C13H20N5S2; calc. 310.1155).  
1-Cyclohexyl-5-methyl-4-[5-(4-sulfophenyl)amino]-1,3,4-thiadiazol-2-yl)-1H-
imidazole-2(3H)-thione (11b). Yield: 0.338 g (91%). Colorless crystals. M.p. 314 – 316º 
(dec., MeOH). IR (KBr): 3400–2700m (br), 3178s, 2935s, 1405s (br), 1122s (br), 616m. 
1H-NMR ((D6)DMSO): 7.57 (br. s, 4 arom. H); 3.36 – 3.29 (m, CH); 2.57 (s, Me); 1.94 
– 1.63 (m, 6 cyclohexyl H); 1.37 – 1.21 (m, 4 cyclohexyl H); NH absorption missing. 
13C-NMR ((D6)DMSO): 163.9, 147.3 (thiadiazole C(2), C(5)); 162.9 (C=S); 142.9, 
123.0, 120.2, 116.8 (2 arom. C, imidazole C(4), C(5)); 140.1, 127.1 (4 arom. CH); 57.1 
(CH); 26.3, 25.3, 21.2 (5 cyclohexyl CH2); 11.9 (Me). HR-ESI-MS: 474.0695 
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1a R1 = Bn
  b R1 = Me
  c R1 = cHex
2a R1 = Bn
  b R1 = Me






































4a R1 = Bn, R2 = Me
  b R1 = Bn, R2 = Ph
  c R1 = Bn, R2 = Bu
  d R1 = Bn, R2 = tBu
  e R1 = Me, R2 = Me
  f  R1 = Me, R2 = Ph
  g R1 = Me, R2 = Bu
  h R1 = cHex, R2 = Me
  i  R1 = cHex, R2 = Ph























5a R1 = Bn, R2 = Me
  b R1 = Bn, R2 = Ph
  c R1 = Bn, R2 = Bu
  d R1 = Me, R2 = Me
  e R1 = Me, R2 = Ph
  f  R1 = Me, R2 = Bu
  g R1 = cHex, R2 = Me
  h R1 = cHex, R2 = Ph
  i  R1 = cHex, R2 = Bu
6a R1 = Bn, R2 = Me
  b R1 = Bn, R2 = 4-HO3SC6H4
  c R1 = Bn, R2 = Bu
  d R1 = Me, R2 = Me
























































7a R1 = Bn
  b  R1 = Me
8a R1 = Bn
  b R1 = Me
1a R1 = Bn




















9a R1 = Bn
  b R1 = cHex
(MeCO)2O
1a R1 = Bn



















































































































SS CH2Cl2, r.t. SS CH2Cl2, r.t.
